S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
TSE:ASP

Acerus Pharmaceuticals - ASP Stock Forecast, Price & News

C$0.36
0.00 (0.00%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
C$0.36
C$0.36
50-Day Range
C$0.28
C$1.29
52-Week Range
C$0.28
C$10.00
Volume
N/A
Average Volume
4,719 shs
Market Capitalization
C$2.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ASP stock logo

About Acerus Pharmaceuticals (TSE:ASP) Stock

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Receive ASP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASP Stock News Headlines

IIROC Trading Halt - ASP
Acerus Files For CCAA Protection
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Acerus Reports First Quarter 2022 Financial Results
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Stocks in play: Acerus Pharmaceuticals Corporation.
Acerus Announces Amendment to Loan Facilities
Acerus Announces Amendments to Loan Facilities
Acerus Pharmaceuticals Corp.
Acerus Provides Update on Litigation with Recipharm
Acerus Pharmaceuticals Corp
Acerus Reports First Quarter 2021 Financial Results
See More Headlines
Receive ASP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASP Company Calendar

Last Earnings
11/14/2022
Today
2/04/2023
Next Earnings (Estimated)
3/13/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$3.04 million
Cash Flow
C$0.11 per share
Book Value
C($1.80) per share

Miscellaneous

Free Float
N/A
Market Cap
C$2.77 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Edward Gudaitis
    Pres, CEO & Director
  • Mr. Gavin Damstra
    Sr. VP of International Commercial
  • Dr. Christopher Sorli F.A.C.E.
    M.D., Ph.D., Chief Medical Officer
  • Mr. Kevin Thomas Hickey
    Sr. VP of US Commercial
  • Mr. Naveed Manzoor
    Interim Chief Financial Officer
  • Mr. Chris Witty
    Investor Relations
  • Mr. Philippe Savard
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Mr. Hubert Tomasz Czerwinski
    Pres of Acerus Pharmaceuticals SRL













ASP Stock - Frequently Asked Questions

How have ASP shares performed in 2023?

Acerus Pharmaceuticals' stock was trading at C$0.81 at the beginning of 2023. Since then, ASP shares have decreased by 55.6% and is now trading at C$0.36.
View the best growth stocks for 2023 here
.

When is Acerus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our ASP earnings forecast
.

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (TSE:ASP) posted its quarterly earnings data on Monday, November, 14th. The company reported ($0.71) EPS for the quarter. The company had revenue of $1.01 million for the quarter.

What other stocks do shareholders of Acerus Pharmaceuticals own?
What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ASP."

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Acerus Pharmaceuticals' stock price today?

One share of ASP stock can currently be purchased for approximately C$0.36.

How much money does Acerus Pharmaceuticals make?

Acerus Pharmaceuticals (TSE:ASP) has a market capitalization of C$2.77 million and generates C$3.04 million in revenue each year.

How can I contact Acerus Pharmaceuticals?

The official website for the company is www.aceruspharma.com. The company can be reached via phone at 416-679-0771.

This page (TSE:ASP) was last updated on 2/5/2023 by MarketBeat.com Staff